7 Amendments of Bogdan Brunon WENTA related to 2018/0225(COD)
Amendment 121 #
Proposal for a decision
Annex I – part II – point 1 – point 1.1 – paragraph 3
Annex I – part II – point 1 – point 1.1 – paragraph 3
Health research and innovation research and innovationincluding product development have played a significant part in this achievement but also in improving productivity and quality in the health and care industry. However, the EU continues to face novel, newly emerging or persisting challenges that are threatening its citizens and public health, the sustainability of its health care and social protection systems, as well as the competitiveness of its health and care industry. Major health challenges in the EU include: the lack of effective health promotion and disease prevention; the rise of non-communicable diseases; the spread of antimicrobial drug resistance and the emergence of infectious epidemics; increased environmental pollution; the persistence of health inequalities among and within countries affecting disproportionally people that are disadvantaged or in vulnerable stages of life; the detection, understanding, control, prevention and mitigation of health risks in a rapidly changing social, urban and natural environment; the increasing costs for European health care systems and the progressive introduction of personalised medicine approaches and digitalisation in health and care; and the increasing pressure on the European health and care industry to remain competitive in and by developing health innovation vis-a-vis new and emerging global players.
Amendment 122 #
Proposal for a decision
Annex I – part II – point 1 – point 1.1 – paragraph 4
Annex I – part II – point 1 – point 1.1 – paragraph 4
These health challenges are complex, interlinked and global in nature and require multidisciplinary, cross-sectorial and transnational collaborations. Research and innovation activities will build close linkages between discovery, clinical, epidemiological, environmental and socio- economic research as well as with regulatory sciences. They will harness the combined skills of academia, not-for-profit product developers and industry and foster their collaboration with health services, patients, policy-makers and citizens in order to leverage on public funding and ensure the uptake of results in clinical practice as well as in health care systems. They will foster strategic collaboration at EU and international level in order to pool the expertise, capacities and resources needed to create economies of scale, scope and speed as well as to share the expected benefits and financial risks involved.
Amendment 128 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 1
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 1
Protecting people against cross-border health threats and poverty-related and neglected diseases is a major challenge for public health, calling for effective international cooperation at EU and global level. This will involve as well as coordination between EU funding instruments in R&I and international development. This will involve developing tools for prevention, preparedness, early detection, treatment and cure of infectious diseases , and also tackling antimicrobial resistance (AMR) following a ‘One Health approach’.
Amendment 131 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 3
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 3
– VNew development and optimisation of vaccines, diagnostics, treatments and cures for infectious diseases, including co- morbidities and co-infections; with priority for poverty-related and neglected diseases where commercial markets are lacking;
Amendment 134 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 5
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 5
– Barriers to the implementation and uptake of medical interventions in clinical practice as well as in the health system, including regulatory strengthening in low- and middle-income countries;
Amendment 138 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 6
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 6
– Trans-border aspects ofand research and product development in infectious diseases and specific challenges in low- and middle-income countries (LMICs), such as tuberculosis, HIV and malaria as well as neglected tropical diseases.
Amendment 165 #
– Research on newly emerging health issues and health threats, large scale epidemics of infectious diseases and health threats with special attention for the threat of antimicrobial resistance.